August 20, 2024
Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity
Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
Navigating Challenges and Opportunities in the 2024 Life Sciences Industry Outlook
Life Sciences Industry, 2024 Outlook, Biotechnology, Medical Devices, Artificial Intelligence, Drug Pricing, Regulatory Changes, Supply Chain Security, Talent Shortage
Adcendo Secures $1 Billion Deal for Multitude’s Anti-TF ADC
Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment
Avantor Divests Clinical Services Unit to Audax Private Equity for $650 Million
Avantor, Clinical Services, Audax Private Equity, Divestiture, Laboratory Products, Bioscience Production
TYK Medicines Secures $74M in Hong Kong IPO to Advance EGFR Cancer Therapy
TYK Medicines, IPO, EGFR cancer therapy, Hong Kong, biotech funding
Walgreens and BARDA Collaborate on $100M Decentralized Clinical Trials Initiative
Walgreens, BARDA, Decentralized Clinical Trials, $100M Partnership, Healthcare Research